Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2023
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's diseaseRobert A Rissman, Oliver Langford, Rema Raman, et al.
The Journal of Prevention of Alzheimer'S Disease|October 25, 2022
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task ForceD Angioni, J Delrieu, O Hansson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 16, 2024
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloidMatthew R Meyer, Kristopher M Kirmess, Stephanie Eastwood, et al.
Brain : a Journal of Neurology|February 25, 2026
Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognitionPetrice M Cogswell, Emily S Lundt, Terry M Therneau, et al.
Nature Medicine|April 9, 2025
Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platformSebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, et al.
JAMA Network Open|April 21, 2022
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive ImpairmentYan Hu, Kristopher M Kirmess, Matthew R Meyer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 30, 2025
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individualsPetrice M Cogswell, Heather J Wiste, Terry M Therneau, et al.
Nature Communications|April 14, 2026
Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adultsHyun-Sik Yang, Juliana A U Anzai, Wai-Ying Wendy Yau, et al.
JAMA Neurology|February 2, 2026
Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and AnemiaJihwan Yun, Jungah Lee, Daeun Shin, et al.
Nature Reviews. Neurology|June 12, 2024
Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's DiseaseSuzanne E Schindler, Douglas Galasko, Ana C Pereira, et al.
Pageof 8